Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets
Colon cancer (CC) belongs to the three major malignancies with a high recurrence rate. Therefore, a novel drug delivery system that can prevent CC recurrence while minimizing side effects is needed. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has recently been spotlighted as a pr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Gels |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2310-2861/8/7/427 |
| _version_ | 1827597009464328192 |
|---|---|
| author | Sungjun Kim Yerim Jwa Jiyeon Hong Kyobum Kim |
| author_facet | Sungjun Kim Yerim Jwa Jiyeon Hong Kyobum Kim |
| author_sort | Sungjun Kim |
| collection | DOAJ |
| description | Colon cancer (CC) belongs to the three major malignancies with a high recurrence rate. Therefore, a novel drug delivery system that can prevent CC recurrence while minimizing side effects is needed. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has recently been spotlighted as a protein drug that can induce apoptosis of cancer cells specifically. However, its short in vivo half-life is still a challenge to overcome. Hence, in this study, a gel-like mPEGylated coacervate (mPEG-Coa) delivery platform was developed through electrostatic interaction of mPEG-poly(ethylene arginylaspartate diglyceride) (mPEG-PEAD) and heparin for effective protection of cargo TRAIL, subsequently preserving its bioactivity. mPEG-Coa could protect cargo TRAIL against protease. Sustained release was observed for a long-term (14 days). In addition, recurrence of HCT-116 cells was suppressed when cells were treated with TRAIL-loaded mPEG-Coa for 7 days through long-term continuous supply of active TRAIL, whereas re-proliferation occurred in the bolus TRAIL-treated group. Taken together, these results suggest that our gel-like mPEG-Coa could be utilized as a functional delivery platform to suppress CC recurrence by exogenously supplying TRAIL for a long time with a single administration. |
| first_indexed | 2024-03-09T03:23:15Z |
| format | Article |
| id | doaj.art-182f4a4c2e4a466f91b41768e2bca79c |
| institution | Directory Open Access Journal |
| issn | 2310-2861 |
| language | English |
| last_indexed | 2024-03-09T03:23:15Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gels |
| spelling | doaj.art-182f4a4c2e4a466f91b41768e2bca79c2023-12-03T15:05:13ZengMDPI AGGels2310-28612022-07-018742710.3390/gels8070427Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate MicrodropletsSungjun Kim0Yerim Jwa1Jiyeon Hong2Kyobum Kim3Department of Chemical & Biochemical Engineering, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaDepartment of Chemical & Biochemical Engineering, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaDepartment of Chemical & Biochemical Engineering, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaDepartment of Chemical & Biochemical Engineering, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul 22012, KoreaColon cancer (CC) belongs to the three major malignancies with a high recurrence rate. Therefore, a novel drug delivery system that can prevent CC recurrence while minimizing side effects is needed. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has recently been spotlighted as a protein drug that can induce apoptosis of cancer cells specifically. However, its short in vivo half-life is still a challenge to overcome. Hence, in this study, a gel-like mPEGylated coacervate (mPEG-Coa) delivery platform was developed through electrostatic interaction of mPEG-poly(ethylene arginylaspartate diglyceride) (mPEG-PEAD) and heparin for effective protection of cargo TRAIL, subsequently preserving its bioactivity. mPEG-Coa could protect cargo TRAIL against protease. Sustained release was observed for a long-term (14 days). In addition, recurrence of HCT-116 cells was suppressed when cells were treated with TRAIL-loaded mPEG-Coa for 7 days through long-term continuous supply of active TRAIL, whereas re-proliferation occurred in the bolus TRAIL-treated group. Taken together, these results suggest that our gel-like mPEG-Coa could be utilized as a functional delivery platform to suppress CC recurrence by exogenously supplying TRAIL for a long time with a single administration.https://www.mdpi.com/2310-2861/8/7/427TRAILcoacervatecolon cancercancer recurrencedrug delivery system |
| spellingShingle | Sungjun Kim Yerim Jwa Jiyeon Hong Kyobum Kim Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets Gels TRAIL coacervate colon cancer cancer recurrence drug delivery system |
| title | Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets |
| title_full | Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets |
| title_fullStr | Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets |
| title_full_unstemmed | Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets |
| title_short | Inhibition of Colon Cancer Recurrence via Exogenous TRAIL Delivery Using Gel-like Coacervate Microdroplets |
| title_sort | inhibition of colon cancer recurrence via exogenous trail delivery using gel like coacervate microdroplets |
| topic | TRAIL coacervate colon cancer cancer recurrence drug delivery system |
| url | https://www.mdpi.com/2310-2861/8/7/427 |
| work_keys_str_mv | AT sungjunkim inhibitionofcoloncancerrecurrenceviaexogenoustraildeliveryusinggellikecoacervatemicrodroplets AT yerimjwa inhibitionofcoloncancerrecurrenceviaexogenoustraildeliveryusinggellikecoacervatemicrodroplets AT jiyeonhong inhibitionofcoloncancerrecurrenceviaexogenoustraildeliveryusinggellikecoacervatemicrodroplets AT kyobumkim inhibitionofcoloncancerrecurrenceviaexogenoustraildeliveryusinggellikecoacervatemicrodroplets |